KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Interest Expenses (2018 - 2025)

Historic Interest Expenses for TherapeuticsMD (TXMD) over the last 12 years, with Q3 2025 value amounting to $3000.0.

  • TherapeuticsMD's Interest Expenses changed 0.0% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7000.0, marking a year-over-year decrease of 1250.0%. This contributed to the annual value of $32.9 million for FY2021, which is 1517.09% up from last year.
  • TherapeuticsMD's Interest Expenses amounted to $3000.0 in Q3 2025, which was down 0.0% from $2000.0 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Interest Expenses peaked at $14.4 million during Q1 2022, and registered a low of $2000.0 during Q1 2025.
  • For the 5-year period, TherapeuticsMD's Interest Expenses averaged around $3.7 million, with its median value being $45000.0 (2023).
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 6331.84% in 2021, then crashed by 9965.31% in 2023.
  • TherapeuticsMD's Interest Expenses (Quarter) stood at $7.6 million in 2021, then skyrocketed by 90.23% to $14.4 million in 2022, then plummeted by 99.86% to $20000.0 in 2023, then crashed by 85.0% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025.
  • Its last three reported values are $3000.0 in Q3 2025, $2000.0 for Q2 2025, and $2000.0 during Q1 2025.